Dianthus Therapeutics, Inc. /DE/ Revenue from Contract with Customer, Excluding Assessed Tax
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Revenue from Contract with Customer, Excluding Assessed Tax of $2.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-09
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $284.00K, a 78.58% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $396.00K, a 81.77% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $193.00K, a 89.64% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.16M, a 33.07% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.04M, a 67.35% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for fiscal 2024 was $6.24M, a 120.63% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.83M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $680.00K derived: sum of 2 quarters · filed 2026-03-09 | $873.00K derived: sum of 3 quarters · filed 2026-03-09 | $2.04M 10-K · filed 2026-03-09 |
| 2025-09-30 | $396.00K 10-Q · filed 2025-11-05 | $589.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.75M 10-Q · filed 2025-11-05 | $3.08M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $193.00K 10-Q · filed 2025-08-07 | $1.36M 10-Q · filed 2025-08-07 | $2.68M derived: sum of 3 quarters · filed 2026-03-09 | $4.85M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $1.16M 10-Q · filed 2025-05-12 | $2.49M derived: sum of 2 quarters · filed 2026-03-09 | $4.66M derived: sum of 3 quarters · filed 2026-03-09 | $6.52M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.50M derived: sum of 2 quarters · filed 2026-03-09 | $5.36M derived: sum of 3 quarters · filed 2026-03-09 | $6.24M 10-K · filed 2026-03-09 |
| 2024-09-30 | $2.17M 10-Q · filed 2025-11-05 | $4.04M derived: sum of 2 quarters · filed 2025-11-05 | $4.91M 10-Q · filed 2025-11-05 | $5.37M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.86M 10-Q · filed 2025-08-07 | $2.74M 10-Q · filed 2025-08-07 | $3.19M derived: sum of 3 quarters · filed 2025-08-07 | $4.12M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $874.00K 10-Q · filed 2025-05-12 | $1.33M derived: sum of 2 quarters · filed 2025-05-12 | $2.25M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.38M derived: sum of 2 quarters · filed 2025-03-11 | $2.83M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $924.00K 10-Q · filed 2023-11-09 | $2.37M 10-Q · filed 2023-11-09 | ||
| 2022-12-31 | $1.18M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | $2.35M derived: sum of 2 quarters · filed 2023-12-21 | $6.42M 8-K · filed 2023-12-21 | |
| 2022-09-30 | $1.17M 10-Q · filed 2023-11-09 | $5.24M 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $1.48M 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |